408 related articles for article (PubMed ID: 17848143)
1. Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.
Radović S; Babić M; Dorić M; Hukić A; Kuskunović S; Hadzismajlović A; Serdarević F
Bosn J Basic Med Sci; 2007 Aug; 7(3):205-11. PubMed ID: 17848143
[TBL] [Abstract][Full Text] [Related]
2. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2.
Nguyen VN; Mirejovský P; Mirejovský T; Melínová L; Mandys V
Acta Histochem; 2000 Aug; 102(3):323-38. PubMed ID: 10990069
[TBL] [Abstract][Full Text] [Related]
3. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
4. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion.
Bubb RS; Komaki R; Hachiya T; Milas I; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1216-24. PubMed ID: 12128123
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
6. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome.
Mishina T; Dosaka-Akita H; Kinoshita I; Hommura F; Morikawa T; Katoh H; Kawakami Y
Br J Cancer; 1999 Jun; 80(8):1289-95. PubMed ID: 10376986
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
[TBL] [Abstract][Full Text] [Related]
9. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.
Lai RS; Wang JS; Hsu HK; Chang HC; Lin CH; Lin MH
Jpn J Clin Oncol; 2002 Oct; 32(10):393-7. PubMed ID: 12451034
[TBL] [Abstract][Full Text] [Related]
10. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity and Bcl-2 expression in non-small cell lung cancer.
Ohmura Y; Aoe M; Andou A; Shimizu N
Clin Cancer Res; 2000 Aug; 6(8):2980-7. PubMed ID: 10955774
[TBL] [Abstract][Full Text] [Related]
13. Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer.
Nagy B; Tiszlavicz L; Eller J; Molnar J; Thurzo L
In Vivo; 2003; 17(1):93-6. PubMed ID: 12655798
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
15. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.
Dosaka-Akita H; Hommura F; Mishina T; Ogura S; Shimizu M; Katoh H; Kawakami Y
Cancer Res; 2001 Mar; 61(6):2500-4. PubMed ID: 11289121
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
20. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer.
Meert AP; Martin B; Verdebout JM; Paesmans M; Berghmans T; Ninane V; Sculier JP
Lung Cancer; 2004 Jun; 44(3):295-301. PubMed ID: 15140542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
